SYK STRYKER CORPORATION

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.

“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”

After closing, VB Spine will become a strategic partner to Stryker with exclusive access to Mako Spine and Copilot for use with VB Spine’s implants in spine procedures. The transaction will enhance the focus of both Stryker and VB Spine to meet the needs of customers and their patients and is expected to achieve faster growth and deliver greater value for all stakeholders.

“We have long admired Stryker for its comprehensive spine portfolio, incredible talent, and strong culture,” said Marc, John and Anthony Viscogliosi, Co-Founders of Viscogliosi Brothers, LLC. “We see a tremendous opportunity to provide the focus, surgeon-centric innovation, and commercial execution needed to grow the business and further impact patient lives and outcomes.”

The definitive agreement also includes a binding offer to acquire Stryker’s spinal implants business in France, subject to required consultations with employees and/or employee representatives. The sale of Stryker’s spinal implants business in other international markets is anticipated, pending satisfaction of legal and regulatory requirements, including any required consultations. The transaction is expected to close in the U.S. in the first half of 2025, subject to customary closing conditions.  Stryker’s U.S. spinal implants business and VB Spine will continue to operate as separate entities and proceed with business as usual until the transaction closes.

In connection with the transaction, Barings, LLC is an investor and financial partner to Viscogliosi Brothers.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at .

About Viscogliosi Brothers

Viscogliosi Brothers is a family-owned New York City-based family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 42 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of multiple businesses in the spine industry specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma and Woven Orthopedics Technologies, among others. For more information, visit .

About Barings

Barings is a $421+ billion* global asset management firm that partners with institutional, insurance, and intermediary clients, and supports leading businesses with flexible financing solutions. The firm, a subsidiary of MassMutual, seeks to deliver excess returns by leveraging its global scale and capabilities across public and private markets in fixed income, real assets and capital solutions.

*Assets under management as of December 31, 2024

Contacts

For investor inquiries please contact:

Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or

John Nguyen, Senior Director, Investor Relations at 269-385-2600 or

For media inquiries please contact:

Jenny Braga, Director, Communications and Public Relations at 269-385-2600 or



EN
28/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRYKER CORPORATION

 PRESS RELEASE

Stryker to announce financial results for its first quarter of fiscal ...

Stryker to announce financial results for its first quarter of fiscal year 2025 Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its first quarter 2025 results.  ...

 PRESS RELEASE

Stryker completes sale of U.S. spinal implants business

Stryker completes sale of U.S. spinal implants business Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC. “The sale of our spinal implants business enhances our strategic focus, positioning us to meet evolving customer needs and invest where we see the greatest opportunity for innovation and long-term growth,” said Kevin Lobo, Chair and CEO, Stryker. “We remain...

 PRESS RELEASE

Stryker announces intention to nominate Manny Maceda to board of direc...

Stryker announces intention to nominate Manny Maceda to board of directors Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025. Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partner and...

 PRESS RELEASE

Stryker announces Annual Meeting of Shareholders

Stryker announces Annual Meeting of Shareholders Portage, Michigan, March 25, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2025 Annual Meeting of Shareholders is scheduled as follows: Thursday, May 8, 2025 – 9:30 a.m. Eastern Time The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at . To listen to the meeting as a guest dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker...

 PRESS RELEASE

Stryker completes acquisition of Inari Medical, Inc., providing entry ...

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. “The acquisition of ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch